

Hirsutosterols A–G, polyoxygenated steroids from a Formosan soft coral  
*Cladiella hirsuta*†Bo-Wei Chen,<sup>a</sup> Shu-Ming Chang,<sup>a</sup> Chiung-Yao Huang,<sup>a</sup> Jui-Hsin Su,<sup>b</sup> Zhi-Hong Wen,<sup>a</sup>  
Yang-Chang Wu<sup>c</sup> and Jyh-Horng Sheu<sup>\*a,d</sup>

Received 20th January 2011, Accepted 24th February 2011

DOI: 10.1039/c1ob05106g

Seven new polyoxygenated steroids, hirsutosterols A–G (**1–7**), were isolated from the Formosan soft coral *Cladiella hirsuta*. Their structures were elucidated by spectroscopic methods, particularly in 1D and 2D NMR experiments. The absolute configurations of **1** and **5** were determined by Mosher's method. Sterols **4–6** possess hydroxy groups at C-9 and C-11 and might be oxidatively cleaved to the corresponding 9,11-secosterols. Hirsutosterol A (**1**) was found to exhibit a stronger cytotoxicity against a limited panel of cancer cell lines.

## Introduction

In the course of our chemical study on the octocorals, metabolites with promising anti-inflammatory and/or cytotoxic activities, including sesquiterpenoids,<sup>1,2</sup> cembranoids,<sup>3–5</sup> eunicellins<sup>6–8</sup> and steroids,<sup>9–10</sup> have been discovered. As many secondary metabolites have been isolated from soft corals of the genus *Cladiella*,<sup>11–25</sup> we investigated the chemical constituents of a Formosan soft coral *Cladiella hirsuta* which has not been chemically studied before with the aim of discovering bioactive natural products. The above study has led to the isolation of a series of eunicellin-type metabolites.<sup>26</sup> In this paper, we report the isolation, structure determination and biological activity of seven new polyoxygenated steroids, hirsutosterols A–G (**1–7**, Scheme 1), from further investigation of the soft coral *C. hirsuta*. The structures of **1–7** were established by extensive spectroscopic analysis, including 2D NMR (<sup>1</sup>H–<sup>1</sup>H COSY, HSQC, HMBC, and NOESY) spectroscopy. Cytotoxicity of metabolites **1–7** against a limited panel of human tumor cell lines including human liver carcinoma (Hep G2 and Hep G3B), human breast carcinoma (MDA-MB-231 and MCF-7) human lung carcinoma (A-549), and human oral cancer cells (Ca9-22) was investigated, and the ability of **1–7** to inhibit up-regulation of the pro-inflammatory iNOS (inducible nitric oxide synthase) and COX-2 (cyclooxygenase-2) proteins in LPS (lipopolysaccharide)-stimulated RAW264.7 macrophage cells was

also evaluated. Herein, we report the isolation, structure elucidation and bioactivities of their natural products.

## Results and discussion

The soft coral was extracted with acetone. The organic extract was concentrated to an aqueous suspension and was further partitioned between EtOAc and water. The combined EtOAc-soluble fraction was concentrated under reduced pressure and the residue was repeatedly purified by chromatography to yield metabolites **1–7**.

Hirsutosterol A (**1**) was isolated as a white powder. Its HRESIMS exhibited a [M + Na]<sup>+</sup> peak at *m/z* 513.3552 and established a molecular formula C<sub>30</sub>H<sub>50</sub>O<sub>5</sub>, implying six degrees of unsaturation. The IR spectrum of **1** revealed the presence of hydroxy, ester, and conjugated enone functionalities from absorptions of 3317, 1737, and 1669 cm<sup>-1</sup>. The <sup>13</sup>C NMR spectroscopic data of **1** exhibited thirty carbon signals (Table 1), which were assigned by the assistance of DEPT spectrum to seven methyls, nine methylenes (including one oxymethylene), nine sp<sup>3</sup> methines (including two oxymethines), and three sp<sup>2</sup> and two sp<sup>3</sup> quaternary carbons. The carbonyl and olefinic resonances in the <sup>13</sup>C NMR spectrum data of **1** (Table 1) appeared at δ 205.1 (qC), 147.8 (CH) and 136.6 (qC), respectively, revealing the presence of a conjugated enone. The 3H singlet appearing at δ 2.04 in the <sup>1</sup>H NMR spectrum (Table 3) and the carbonyl signal at δ 170.5 in the <sup>13</sup>C NMR spectrum were ascribable to an acetoxy group. Therefore, the remaining three degrees of unsaturation identified compound **1** as a tricyclic compound. Detailed analysis of the <sup>1</sup>H–<sup>1</sup>H COSY and HMBC correlations (Fig. 1) further established the molecular skeleton of **1** as a 9,11-secosterol derivative bearing two hydroxy groups at C-6 and C-11, one acetoxy group at C-3, and a conjugated enone at olefinic carbons C-7 and C-8, and carbonyl carbon C-9. From the above results, the structure of compound **1** was shown to be very similar to


<sup>a</sup>Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung, 804, Taiwan. E-mail: sheu@mail.nsysu.edu.tw; Fax: +886-7-5255020; Tel: +886-7-5252000, ext. 5030

<sup>b</sup>Taiwan Coral Research Center, National Museum of Marine Biology & Aquarium, Checheng, Pingtung, 944, Taiwan

<sup>c</sup>Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, 807, Taiwan

<sup>d</sup>Asia-Pacific Ocean Research Center, National Sun Yat-sen University, Kaohsiung, 804, Taiwan

† Electronic supplementary information (ESI) available: <sup>1</sup>H, <sup>13</sup>C NMR, and ESIMS spectra of **1–7**. See DOI: 10.1039/c1ob05106g



Scheme 1



that of a known compound, 3 $\beta$ ,6 $\alpha$ ,11-trihydroxy-9,11-seco-5 $\alpha$ -cholest-7-ene-9-one.<sup>27</sup> The relative configuration of **1** was mostly confirmed to be the same as that of 3 $\beta$ ,6 $\alpha$ ,11-trihydroxy-9,11-seco-5 $\alpha$ -cholest-7-ene-9-one by comparison of the chemical shifts and coupling constants for the protons of both compounds and was further confirmed by NOE correlations (Fig. 2). Furthermore, the 24S configuration of **1** was determined by comparison of the NMR data with those of yonarasterol **B** which was isolated from the soft coral *Clavularia viridis*.<sup>28</sup> The proton shift of H<sub>3</sub>-28,  $\delta_{\text{H}} = 0.78$  ppm, was found to be identical with that of yonarasterol **B**. Also, the carbon shifts of C-21–C-28 are in excellent agreement with those of yonarasterol **B** and (24S)-methylcholestanol (*vs* those of (24R)-methylcholestanol).<sup>29</sup> Thus, the structure of compound **1** was fully established. In order to resolve the absolute structure of **1**, we determined the configuration at C-6 using Mosher's method.<sup>30,31</sup> The *S*- and *R*- $\alpha$ -methoxy- $\alpha$ -trifluoromethylphenylacetic (MTPA) esters of **1** (**1a** and **1b**, respectively) were prepared by using the corresponding *R*-(-)- and *S*-(+)- $\alpha$ -methoxy- $\alpha$ -(trifluoromethyl)phenylacetyl chlorides, respectively. The values

**Table 1** <sup>13</sup>C NMR data for compounds **1**–**4**

Position	<b>1</b> <sup>a</sup>	<b>2</b> <sup>b</sup>	<b>3</b> <sup>c</sup>	<b>4</b> <sup>b</sup>
1	31.6, CH <sub>2</sub> <sup>d</sup>	31.6, CH <sub>2</sub>	31.6, CH <sub>2</sub>	31.8, CH <sub>2</sub>
2	26.4, CH <sub>2</sub>	26.4, CH <sub>2</sub>	26.7, CH <sub>2</sub>	27.2, CH <sub>2</sub>
3	72.2, CH	72.0, CH	72.0, CH	72.6, CH
4	29.0, CH <sub>2</sub>	29.0, CH <sub>2</sub>	29.0, CH <sub>2</sub>	30.2, CH <sub>2</sub>
5	48.3, CH	48.4, CH	48.5, CH	42.7, CH
6	69.0, CH	69.4, CH	69.4, CH	69.9, CH
7	147.8, CH	147.2, CH	147.2, CH	127.9, CH
8	136.6, qC	136.9, qC	137.1, qC	140.0, qC
9	205.1, qC	204.9, qC	204.9, qC	74.3, qC
10	44.7, qC	44.8, qC	44.8, qC	40.5, qC
11	59.2, CH <sub>2</sub>	59.4, CH <sub>2</sub>	59.4, CH <sub>2</sub>	69.4, CH <sub>2</sub>
12	40.8, CH <sub>2</sub>	40.8, CH <sub>2</sub>	40.8, CH <sub>2</sub>	46.8, CH <sub>2</sub>
13	46.0, qC	46.1, qC	46.2, qC	42.9, qC
14	42.5, CH	42.5, CH	42.3, CH	50.6, CH
15	26.5, CH <sub>2</sub>	26.6, CH <sub>2</sub>	27.5, CH <sub>2</sub>	22.9, CH <sub>2</sub>
16	26.2, CH <sub>2</sub>	26.2, CH <sub>2</sub>	26.6, CH <sub>2</sub>	27.9, CH <sub>2</sub>
17	49.5, CH	49.4, CH	50.5, CH	55.8, CH
18	17.3, CH <sub>3</sub>	17.3, CH <sub>3</sub>	17.2, CH <sub>3</sub>	12.2, CH <sub>3</sub>
19	16.0, CH <sub>3</sub>	16.1, CH <sub>3</sub>	15.7, CH <sub>3</sub>	15.5, CH <sub>3</sub>
20	35.3, CH	34.9, CH	39.2, CH	36.0, CH
21	18.8, CH <sub>3</sub>	18.6, CH <sub>3</sub>	18.3, CH <sub>3</sub>	18.7, CH <sub>3</sub>
22	33.0, CH <sub>2</sub>	34.0, CH <sub>2</sub>	24.0, CH <sub>2</sub>	35.9, CH <sub>2</sub>
23	31.2, CH <sub>2</sub>	31.5, CH <sub>2</sub>	24.6, CH <sub>2</sub>	23.8, CH <sub>2</sub>
24	39.0, CH	156.6, qC	44.8, qC	39.4, CH
25	31.4, CH	33.7, CH	32.8, CH	28.0, CH
26	17.5, CH <sub>3</sub>	21.8, CH <sub>3</sub>	18.5, CH <sub>3</sub>	22.5, CH <sub>3</sub>
27	20.4, CH <sub>3</sub>	21.9, CH <sub>3</sub>	20.7, CH <sub>3</sub>	22.8, CH <sub>3</sub>
28	15.4, CH <sub>3</sub>	106.1, CH <sub>2</sub>	16.7, CH <sub>3</sub>	
29			10.5, CH <sub>2</sub>	
3-OAc	170.5, qC	170.5, qC	170.5, qC	170.6, qC
	21.2, CH <sub>3</sub>	21.3, CH <sub>3</sub>	21.3, CH <sub>3</sub>	21.4, CH <sub>3</sub>

<sup>a</sup> 75 MHz in CDCl<sub>3</sub>. <sup>b</sup> 100 MHz in CDCl<sub>3</sub>. <sup>c</sup> 125 MHz in CDCl<sub>3</sub>.

<sup>d</sup> Multiplicities deduced by DEPT.

**Fig. 1** Key <sup>1</sup>H–<sup>1</sup>H COSY and HMBC correlations of **1** and **4**.**Fig. 2** Key NOESY correlations of **1**.

of  $\Delta\delta$  [ $\delta$ (*S*-MTPA ester) –  $\delta$ (*R*-MTPA ester)] for H-7 and H-14 were negative, while the values of  $\Delta\delta$  for H-3, H-5 and 3-OAc were positive, revealing the *S*-configuration at C-6 (Fig. 3). It was found that the 3-*O*-deacetyl derivative of **1** has been isolated from a soft coral.<sup>32</sup>


The molecular formula of hirsutosterol **B** (**2**) was assigned as C<sub>30</sub>H<sub>48</sub>O<sub>5</sub> from the HRESIMS and NMR data (Tables 1 and 2).

**Table 2**  $^{13}\text{C}$  NMR data for compounds 5–7

Position	5 <sup>a</sup>	6 <sup>b</sup>	7 <sup>c</sup>
1	31.8, CH <sub>2</sub> <sup>d</sup>	31.8, CH <sub>2</sub>	31.7, CH <sub>2</sub>
2	27.2, CH <sub>2</sub>	27.2, CH <sub>2</sub>	27.1, CH <sub>2</sub>
3	72.8, CH	72.6, CH	72.5, CH
4	30.3, CH <sub>2</sub>	30.2, CH <sub>2</sub>	30.2, CH <sub>2</sub>
5	42.6, CH	42.7, CH	42.8, CH
6	69.8, CH	69.9, CH	69.8, CH
7	127.8, CH	127.9, CH	127.7, CH
8	139.9, qC	140.0, qC	139.8, qC
9	74.4, qC	74.3, qC	74.9, qC
10	40.5, qC	40.5, qC	40.6, qC
11	69.4, CH <sub>2</sub>	69.4, CH <sub>2</sub>	69.7, CH <sub>2</sub>
12	46.7, CH <sub>2</sub>	46.8, CH <sub>2</sub>	43.4, CH <sub>2</sub>
13	42.9, qC	42.9, qC	43.8, qC
14	50.6, CH	50.6, CH	149.1, qC
15	23.0, CH <sub>2</sub>	22.9, CH <sub>2</sub>	118.4, CH
16	27.8, CH <sub>2</sub>	27.8, CH <sub>2</sub>	26.4, CH <sub>2</sub>
17	55.7, CH	55.6, CH	49.1, CH
18	12.2, CH <sub>3</sub>	12.2, CH <sub>3</sub>	19.2, CH <sub>3</sub>
19	15.5, CH <sub>3</sub>	15.5, CH <sub>3</sub>	15.8, CH <sub>3</sub>
20	36.4, CH	36.0, CH	31.9, CH
21	18.9, CH <sub>3</sub>	18.7, CH <sub>3</sub>	15.3, CH <sub>3</sub>
22	33.5, CH <sub>2</sub>	34.3, CH <sub>2</sub>	23.2, CH <sub>2</sub>
23	30.6, CH <sub>2</sub>	30.9, CH <sub>2</sub>	26.2, CH <sub>2</sub>
24	39.0, CH	156.6, qC	33.9, CH
25	31.5, CH	33.8, CH	38.1, CH
26	17.6, CH <sub>3</sub>	21.8, CH <sub>3</sub>	18.0, CH <sub>3</sub>
27	20.5, CH <sub>3</sub>	22.0, CH <sub>3</sub>	20.2, CH <sub>3</sub>
28	15.4, CH <sub>3</sub>	106.1, CH <sub>2</sub>	
29			
3-OAc	170.7, qC	170.6, qC	170.6, qC
	21.4, CH <sub>3</sub>	21.4, CH <sub>3</sub>	21.4, CH <sub>3</sub>

<sup>a</sup> 75 MHz in CDCl<sub>3</sub>, <sup>b</sup> 100 MHz in CDCl<sub>3</sub>, <sup>c</sup> 125 MHz in CDCl<sub>3</sub>.

<sup>d</sup> Multiplicities deduced by DEPT.




**Fig. 3**  $^1\text{H}$  NMR chemical shift differences  $\Delta\delta$  ( $\delta_S - \delta_R$ ) in ppm for the MTPA esters of **1**.

Compound **2** is the 24,28-dehydrogenated derivative of **1**, as shown by the two exocyclic methylene protons resonating at  $\delta$  4.72 (s) and 4.66 (s). This was further confirmed by the HMBC correlations from H<sub>3</sub>-20 to C-17, C-20, C-22; H<sub>2</sub>-23 to C-24; H<sub>3</sub>-26 and H<sub>3</sub>-27 to C-24, C-25; and H<sub>2</sub>-28 to C-23, C-25. Thus, the structure of compound **2** was established. The 3-*O*-deacetyl derivative of **2** has been discovered from marine invertebrates.<sup>33–35</sup>

Hirsutosterol C (**3**) was obtained as a white powder that gave a pseudomolecular ion peak at  $m/z$  525.3559 [M + Na]<sup>+</sup> in the HRESIMS, consistent with the molecular formula C<sub>31</sub>H<sub>50</sub>O<sub>5</sub> and implying seven degrees of unsaturation. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectral data of the A–D rings in **3** were nearly identical with those of **1** and **2**. Furthermore, a cyclopropyl group was found to be present in the side chain [ $\delta_{\text{H}}$  0.54 (1H, m), 0.35 (1H, m), 0.15 (2H, m);  $\delta_{\text{C}}$  24.6 (CH), 24.0 (CH), 10.5 (CH<sub>2</sub>)] of **3**. A methyl substitution at C-24 was revealed by  $^1\text{H}$  NMR ( $\delta$

0.86) and  $^{13}\text{C}$  NMR ( $\delta$  16.7) data. By comparison of the proton shifts of H<sub>3</sub>-21, H<sub>3</sub>-26, H<sub>3</sub>-27, and H<sub>3</sub>-28 with those of the four synthetic demethylgorgosterol isomers,<sup>36</sup> it was suggested that the stereochemistry of the side chain in **3** should be assigned as 22*R*, 23*R*, and 24*R* (Fig. 4). Thus, the structure of compound **3** was established.



**Fig. 4**  $^1\text{H}$  NMR chemical shifts of the side-chain methyl groups of **3** and synthetic isomers of demethylgorgosterols.<sup>36</sup>


Hirsutosterol D (**4**) was isolated as a white powder. Its molecular formula, C<sub>29</sub>H<sub>48</sub>O<sub>5</sub>, was established by the HRESIMS spectrum ( $m/z$  499.3397 [M + Na]<sup>+</sup>) and  $^{13}\text{C}$  NMR data, implying six degrees of unsaturation. The IR absorptions were observed at 3329 and 1733 cm<sup>-1</sup>, suggesting the presence of a hydroxy and carbonyl group. The structure of this compound was deduced from its  $^{13}\text{C}$  NMR and DEPT spectra, which showed that the compound has 29 carbons, including six methyls, nine sp<sup>3</sup> methylenes, one sp<sup>2</sup> methine, eight sp<sup>3</sup> methines (including three oxymethines), and two sp<sup>2</sup> and three sp<sup>3</sup> quaternary carbons. From the  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra (Tables 1 and 3), **4** was found to possess one acetoxy group [ $\delta_{\text{H}}$  2.03, s;  $\delta_{\text{C}}$  170.6 (qC), 21.4 (CH<sub>3</sub>)], in addition to one trisubstituted olefin [ $\delta_{\text{H}}$  5.43, (br s),  $\delta_{\text{C}}$  140.0 (qC), 127.9 (CH)]. Detailed analysis of the  $^1\text{H}$ - $^1\text{H}$  COSY and HMBC correlations (Fig. 1) further established the planar structure of **4** as a cholesterol derivative bearing three hydroxy groups at C-6, C-9 and C-11, one acetoxy group at C-3, and one 7,8-trisubstituted double bond.

**Table 3**  $^1\text{H}$  NMR data for compounds **1–7**

Position	<b>1</b> <sup>a</sup>	<b>2</b> <sup>b</sup>	<b>3</b> <sup>c</sup>	<b>4</b> <sup>b</sup>	<b>5</b> <sup>a</sup>	<b>6</b> <sup>b</sup>	<b>7</b> <sup>c</sup>
1	1.94, m	1.93, m	1.97, m	2.02, m	2.02, m	2.02, m	2.02, m
2	1.53, m	1.53, m	1.55, m	1.76, m	1.76, m	1.76, m	1.78, m
3	1.86, m	1.86, m	1.95, m	1.86, m	1.86, m	1.84, m	1.86, m
4	1.50, m	1.50, m	1.52, m	1.50, m	1.50, m	1.47, m	1.49, m
5	4.64, m	4.66, m	4.66, m	4.68, m	4.65, m	4.66, m	4.68, m
6	2.35 br d (11.9) <sup>d</sup>	2.36 br d (12.0)	2.35 br d (12.5)	2.36, m	2.36, m	2.35, m	2.38, m
7	1.49, m	1.54, m	1.54, m	1.37, m	1.37, m	1.33, m	1.37, m
8	1.84, m	1.84, m	1.85, m	1.76, m	1.76, m	1.74, m	1.78, m
9	4.24, d (9.6)	4.26, d (9.8)	4.26, d (8.5)	3.70, d (9.6)	3.68, d (8.8)	3.70, d (9.6)	3.71, d (9.5)
10	6.60, br s	6.59, br s	6.59, br s	5.43, br s	5.41, br s	5.43, br s	5.49, br s
11	3.84, m	3.89, m	3.90, m	4.11, dd (10.8, 5.2)	4.09, m	4.11, dd (10.4, 4.8)	4.18, t (5.0)
12	3.65, m	3.67, m	3.68, m				
13	1.60, m	1.60, m	1.65, m	2.15, m	2.15, m	2.15, m	2.01, m
14	1.03, m	1.04, m	1.04, m	1.52, m	1.52, m	1.50, m	1.53, m
15	3.38, t (9.7)	3.43, t (9.2)	3.44, t (9.0)	2.34, m	2.34, m	2.34, m	
16	1.91, m	1.95, m	2.11, m	1.56, m	1.56, m	1.58, m	5.02, t (7.0)
17	1.56, m	1.52, m	1.60, m	1.38, m	1.38, m	1.35, m	
18	1.58, m	1.58, m	1.64, m	1.95, m	1.95, m	1.95, m	2.36, m
19	1.40, m	1.42, m	1.64, m	1.28, m	1.28, m	1.32, m	1.94, m
20	1.70, m	1.75, m	1.84, m	1.30, m	1.29, m	1.36, m	2.33, m
21	0.63, s	0.64, s	0.62, s	0.59, s	0.58, s	0.59, s	0.66, s
22	1.14, s	1.15, s	1.15, s	1.03, s	1.02, s	1.03, s	1.04, s
23	1.35, m	1.44, m	0.93, m	1.34, m	1.32, m	1.37, m	1.56, m
24	0.95, d (6.3)	0.99, d (6.8)	0.92, d (6.0)	0.94, d (6.0)	0.95, d (6.5)	0.97, d (6.8)	0.79, d (7.0)
25	1.42, m	1.55, m	0.35, m	1.36, m	1.42, m	1.54, m	1.75, m
26	0.94, m	1.15, m		0.97, m	0.94, m	1.15, m	1.54, m
27	1.38, m	2.10, m	0.54, m	1.32, m	1.38, m	2.07, m	2.36, m
28	0.93, m	1.86, m		1.15, m	0.93, m	1.87, m	1.88, m
29	1.21, m		0.54, m	1.35, m	1.21, m		1.35, m
30				1.12, m			1.12, m
31	1.55, m	2.22, m	1.68, m	1.52, m	1.55, m	2.22, m	1.28, m
32	0.78, d (6.7)	1.02, d (6.8)	0.89, d (7.0)	0.86, d (6.8)	0.78, d (6.5)	1.02, d (6.8)	0.80, d (7.0)
33	0.85, d (6.7)	1.03, d (6.8)	0.90, d (7.0)	0.88, d (6.8)	0.85, d (6.5)	1.03, d (6.8)	0.85, d (7.0)
34	0.78, d (6.7)	4.72, s	0.86, d (7.0)		0.78, d (6.5)	4.72, s	
35		4.66, s				4.66, s	
36			0.15, m				
3-OAc	2.04, s	2.05, s	2.05, s	2.03, s			


<sup>a</sup> 300 MHz in  $\text{CDCl}_3$ . <sup>b</sup> 400 MHz in  $\text{CDCl}_3$ . <sup>c</sup> 500 MHz in  $\text{CDCl}_3$ . <sup>d</sup>  $J$  values (in Hz) in parentheses.

In the NOESY spectrum of **4** (Fig. 5), observation of the NOE correlations between  $\text{H}_3$ -18 with both H-20 and H-11, and  $\text{H}_3$ -19 with H-11, and H-6 suggested that H-20,  $\text{H}_3$ -19,  $\text{H}_3$ -18, H-11, and H-6 are  $\beta$ -oriented. Also, correlations between H-3 with both H-5 and H-4 $\alpha$  ( $\delta$  2.36); and H-17 with both  $\text{H}_3$ -21 and H-14 suggested that  $\text{H}_3$ -21, H-17, H-14, H-5, and H-3 are all  $\alpha$ -oriented. Sterol compounds with a similar oxidation pattern have been previously synthesised from  $\Delta^{7,9(11)}$ -sterols.

**Fig. 5** Key NOESY correlations of **4**.

The HRESIMS spectrum of hirsutosterol (**5**) exhibited a pseudomolecular ion peak at  $m/z$  513.3558  $[\text{M} + \text{Na}]^+$ , consistent with a molecular formula of  $\text{C}_{30}\text{H}_{50}\text{O}_5$ . A comparison of the NMR data of **5** (Tables 2 and 3) with those of **4** and **1** showed

that **5** has the same A–D rings as that of **4** and the identical side chain (C-20–C-28) as that of **1**. The absolute configuration of **5** was also determined by the use of a Mosher's method. The (*S*)- and (*R*)-MTPA esters of **5** (**5a** and **5b**, respectively) were prepared using the corresponding *R*(–)- and *S*(+)- $\alpha$ -methoxy- $\alpha$ -(trifluoromethyl)phenylacetyl chlorides, respectively. The determination of the chemical shift differences ( $\delta_S - \delta_R$ ) for the protons neighboring C-6 led to the assignment of an *S* configuration at C-6 of **5** (Fig. 6), respectively. Thus, the absolute structure of sterol **5** was established. Similarly, the HRESIMS of

**Fig. 6**  $^1\text{H}$  NMR chemical shift differences  $\Delta\delta$  ( $\delta_S - \delta_R$ ) in ppm for the MTPA esters of **5**.



**Table 4** Cytotoxicity data for compounds 1–7

Compound	Cell lines IC <sub>50</sub> (μM)					
	Hep G2	Hep G3B	Ca9-22	A549	MCF-7	MDA-MB-231
1	16.9	9.4	8.2	18.4	17.8	16.1
2	— <sup>a</sup>	8.6	16.0	—	—	—
3	30.1	13.9	11.6	31.3	39.4	30.1
4	30.9	22.5	20.2	31.7	33.4	31.3
5	—	—	—	18.4	—	—
6	32.0	15.2	17.6	—	34.6	26.8
7	35.0	28.1	26.6	38.4	29.7	42.0
Doxorubicin	0.4	1.3	0.2	2.6	2.9	2.0

<sup>a</sup> IC<sub>50</sub> > 50 μM.

hirsutosterol F (**6**) exhibited a [M + Na]<sup>+</sup> peak at *m/z* 511.3396 and established a molecular formula of C<sub>30</sub>H<sub>48</sub>O<sub>5</sub>. The <sup>1</sup>H and <sup>13</sup>C NMR signals of **6** showed that **6** has identical A–D rings as those of **4** and **5**, and the same side chain as that of **2**. Thus, the structure of compound **6** was established.

Hirsutosterol G (**7**), was further isolated as a white solid. Its molecular formula, C<sub>29</sub>H<sub>46</sub>O<sub>5</sub>, was established by HRESIMS. The spectroscopic data of **7** (IR, <sup>1</sup>H and <sup>13</sup>C NMR) were similar to those of **4**, except that a 14,15-carbon, carbon single bond in **4** [δ<sub>C</sub> 50.6, CH, C-14 and 22.9, CH<sub>2</sub>, C-15] were replaced by signals of a trisubstituted double bond [δ<sub>C</sub> 149.1, CH, C-14 and 118.4, CH<sub>2</sub>, C-15] in **7**. This was further confirmed by HMBC correlations observed from H<sub>3</sub>-18 (δ 0.66, s) to C-14 (δ 149.1). The structure of compound **7** was thus established.

The cytotoxicity of compounds 1–7 against the proliferation of a limited panel of cancer cell lines, including human liver (Hep G2 and Hep G3B), breast (MDA-MB-23) and gingival (Ca9-22) carcinoma cells, was evaluated (Table 4). The results showed that secosterol **1**, the more potent one of compounds 1–7, exhibited cytotoxicity towards Hep G2, Hep G3B, MDA-MB-23, and Ca9-22 cancer cell lines with IC<sub>50</sub>s of 16.9, 9.4, 8.2, 18.4, 17.8 and 16.1 μM, respectively. Secosterols **2** and **3** were found to exhibit cytotoxicity towards Hep G3B and Ca9-22 cancer cells. The *in vitro* anti-inflammatory effects of compounds 1–7 were also tested, however, all of 1–7 did not show significant activity in inhibiting the expression of the pro-inflammatory iNOS and COX-2 proteins in LPS-stimulated RAW264.7 macrophage cells.

Compounds 4–7 were isolated from the same organism, thus from a biosynthetic consideration they should possess identical absolute configurations at the chiral centers C-3, C-5, C-6, C-10, C-14, and C-17, in the A–D rings of the steroids.

## Conclusion

Steroids 4–6 possess hydroxy groups at both vicinal carbons, C-9 and C-11, thus, compounds of this type might be oxidatively cleaved to form 9,11-secosterols, such as 1–3. Cholest-7-ene-3β,6α,9α,11α-tetraols (**4–6**) and cholesta-7,14-diene-3β,6α,9α,11α-tetraol (**7**) have unique oxidation patterns which were discovered for the first time. The cytotoxicity data suggest that the 9,11-secosterols 1–3, in particular **1**, are worthy of further anti-tumor study.

## Experimental

### General experimental procedures

Optical rotations were measured on a JASCO P-1020 polarimeter. IR spectra were recorded on a JASCO FT/IR-4100 infrared spectrophotometer. ESIMS were obtained with a Bruker APEX II mass spectrometer. The NMR spectra were recorded on a Varian Unity INOVA 500 FT-NMR at 500 MHz for <sup>1</sup>H and 125 MHz for <sup>13</sup>C or on a Varian 400 MR FT-NMR at 400 MHz for <sup>1</sup>H and 100 MHz for <sup>13</sup>C, or on a Bruker AVANCE-DPX 300 FT-NMR at 300 MHz for <sup>1</sup>H and 75 MHz for <sup>13</sup>C, respectively. Silica gel (Merck, 230–400 mesh) was used for column chromatography. Precoated silica gel plates (Merck, Kieselgel 60 F-254, 0.2 mm) were used for analytical TLC. High-performance liquid chromatography was performed on a Hitachi L-7100 HPLC apparatus with a C-18 column (250 × 21.2 mm, 5 μm).

### Extraction and isolation

The frozen bodies of *C. hirsuta* (3.1 kg, wet wt.) were sliced and exhaustively extracted with acetone (3 × 10 L). The organic extract was concentrated to an aqueous suspension and was further partitioned between EtOAc and H<sub>2</sub>O. The EtOAc layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. After removal of the solvent *in vacuo*, the residue (32.8 g) was subjected to column chromatography on silica gel and eluted with EtOAc in *n*-hexane (0–100% of EtOAc, gradient) and further with MeOH in EtOAc of increasing polarity to yield 25 fractions. Fraction 17, eluted with *n*-hexane–EtOAc (2 : 1), was rechromatographed over a Sephadex LH-20 column, using acetone as the mobile phase to afford four subfractions (A1–A4). Subfraction A2 was separated by reverse-phase HPLC (MeOH–H<sub>2</sub>O, 5 : 1 to 3 : 1) to afford compounds **1** (57.8 mg), **2** (15.6 mg), **3** (1.1 mg), **4** (4.5 mg), **5** (10.2 mg), **6** (4.2 mg), and **7** (1.4 mg), respectively. For <sup>1</sup>H, <sup>13</sup>C NMR, and ESIMS spectra, see ESI.†

**Hirsutosterol A (1):** white powder; [α]<sub>D</sub><sup>25</sup> +26 (*c* 5.78, CHCl<sub>3</sub>); IR (neat) ν<sub>max</sub> 3317, 1737 and 1669 cm<sup>-1</sup>; <sup>13</sup>C and <sup>1</sup>H NMR data (300 MHz; CHCl<sub>3</sub>), see Tables 1 and 3; ESIMS *m/z* 513 [M + Na]<sup>+</sup>; HRESIMS *m/z* 513.3552 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>50</sub>O<sub>5</sub>Na, 513.3556).

**Hirsutosterol B (2):** white powder; [α]<sub>D</sub><sup>25</sup> +32 (*c* 1.56, CHCl<sub>3</sub>); IR (neat) ν<sub>max</sub> 3343, 1737 and 1673 cm<sup>-1</sup>; <sup>13</sup>C and <sup>1</sup>H NMR data (400 MHz; CHCl<sub>3</sub>), see Tables 1 and 3; ESIMS *m/z* 511 [M + Na]<sup>+</sup>; HRESIMS *m/z* 511.3396 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>48</sub>O<sub>5</sub>Na, 511.3399).

**Hirsutosterol C (3):** white powder; [α]<sub>D</sub><sup>25</sup> +33 (*c* 0.11, CHCl<sub>3</sub>); IR (neat) ν<sub>max</sub> 3384, 1735, and 1671 cm<sup>-1</sup>; <sup>13</sup>C and <sup>1</sup>H NMR data (500 MHz; CDCl<sub>3</sub>), see Tables 1 and 3; ESIMS *m/z* 525 [M + Na]<sup>+</sup>; HRESIMS *m/z* 525.3559 [M + Na]<sup>+</sup> (calcd for C<sub>31</sub>H<sub>50</sub>O<sub>5</sub>Na, 525.3556).

**Hirsutosterol D (4):** white powder; [α]<sub>D</sub><sup>25</sup> –44 (*c* 0.45, CHCl<sub>3</sub>); IR (neat) ν<sub>max</sub> 3329 and 1733 cm<sup>-1</sup>; <sup>13</sup>C and <sup>1</sup>H NMR data (400 MHz; CDCl<sub>3</sub>), see Tables 1 and 3; ESIMS *m/z* 499 [M + Na]<sup>+</sup>; HRESIMS *m/z* 499.3397 [M + Na]<sup>+</sup> (calcd for C<sub>29</sub>H<sub>48</sub>O<sub>5</sub>Na, 499.3399).

**Hirsutosterol E (5):** white powder; [α]<sub>D</sub><sup>25</sup> –22 (*c* 1.02, CHCl<sub>3</sub>); IR (neat) ν<sub>max</sub> 3336 and 1735 cm<sup>-1</sup>; <sup>13</sup>C and <sup>1</sup>H NMR data (300 MHz; CDCl<sub>3</sub>), see Tables 2 and 3; ESIMS *m/z* 513 [M + Na]<sup>+</sup>; HRESIMS *m/z* 513.3558 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>50</sub>O<sub>5</sub>Na, 513.3556).

**Hirsutosterol F (6):** white powder; [α]<sub>D</sub><sup>25</sup> –13 (*c* 0.42, CHCl<sub>3</sub>); IR (neat) ν<sub>max</sub> 3328 and 1733 cm<sup>-1</sup>; <sup>13</sup>C and <sup>1</sup>H NMR data (400 MHz;

CDCl<sub>3</sub>), see Tables 2 and 3; ESIMS *m/z* 511 [M + Na]<sup>+</sup>; HRESIMS *m/z* 511.3396 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>48</sub>O<sub>5</sub>Na, 511.3399).

**Hirsutosterol G (7):** white powder; [α]<sub>D</sub><sup>25</sup> -16 (*c* 0.14, CHCl<sub>3</sub>); IR (neat) *v*<sub>max</sub> 3355 and 1733 cm<sup>-1</sup>; <sup>13</sup>C and <sup>1</sup>H NMR data (500 MHz; CDCl<sub>3</sub>), see Tables 2 and 3; ESIMS *m/z* 497 [M + Na]<sup>+</sup>; HRESIMS *m/z* 497.3246 [M + Na]<sup>+</sup> (calcd for C<sub>29</sub>H<sub>46</sub>O<sub>5</sub>Na, 497.3243).

### Preparation of (S)- and (R)-MTPA Esters of 1

To a solution of **1** (0.5 mg) in pyridine (0.4 mL) was added *R*-(-)-α-methoxy-α-(trifluoromethyl)phenylacetyl (MTPA) chloride (25 μL), and the mixture was allowed to stand for 24 h at room temperature. The reaction was quenched by addition of 1.0 mL of water, and the mixture was subsequently extracted with EtOAc (3 × 1.0 mL). The EtOAc-soluble layers were combined, dried over anhydrous MgSO<sub>4</sub> and evaporated. The residue was subjected to column chromatography over silica gel using *n*-hexane–EtOAc (6 : 1) to yield the (*S*)-MTPA ester, **1a** (0.7 mg, 74%). The same procedure was used to prepare the (*R*)-MTPA ester, **1b** (0.6 mg, 63%) from the reaction of (*S*)-MTPA chloride with **1** in pyridine. Selective <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) of **1a**: δ 6.204 (1H, s, H-7), 5.623 (1H, d, *J* = 10.0, H-6), 4.554 (1H, m, H-3), 3.270 (1H, m, H-14), 2.123 (1H, m, H-5), 2.033 (3H, s, 3-OAc). Selective <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) of **1b**: δ 6.345 (1H, s, H-7), 5.597 (1H, d, *J* = 10.0, H-6), 4.363 (1H, m, H-3), 3.304 (1H, m, H-14), 2.019 (1H, m, H-5), 2.019 (1H, s, 3-OAc).

### Preparation of (S)- and (R)-MTPA esters of 5

To a solution of **5** (0.5 mg) in pyridine (0.4 mL) was added *R*-(-)-α-methoxy-α-(trifluoromethyl)phenylacetyl (MTPA) chloride (25 μL), and the mixture was allowed to stand for 24 h at room temperature. The reaction was quenched by addition of 1.0 mL of water, and the mixture was subsequently extracted with EtOAc (3 × 1.0 mL). The EtOAc-soluble layers were combined, dried over anhydrous MgSO<sub>4</sub> and evaporated. The residue was subjected to column chromatography over silica gel using *n*-hexane–EtOAc (6 : 1) to yield the (*S*)-MTPA ester, **5a** (0.6 mg, 83%). The same procedure was used to prepare the (*R*)-MTPA ester, **5b** (0.6 mg, 83%) from the reaction of (*S*)-MTPA chloride with **5** in pyridine. Selective <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) of **5a**: δ 5.190 (1H, d, *J* = 10.4, H-6), 5.178 (1H, s, H-7), 4.584 (1H, m, H-3), 2.293 (1H, m, H-14), 2.122 (1H, m, H-5), 2.025 (3H, s, 3-OAc). Selective <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) of **5b**: δ 5.336 (1H, s, H-7), 5.174 (1H, d, *J* = 10.4, H-6), 4.522 (1H, m, H-3), 2.369 (1H, m, H-14), 2.099 (1H, m, H-5), 2.010 (3H, s, 3-OAc).

### Cytotoxicity testing

Cell lines were purchased from the American Type Culture Collection (ATCC). Cytotoxicity assays were performed using the MTT [3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide] colorimetric method.<sup>37,38</sup>

### In vitro anti-inflammatory assay

Macrophage (RAW264.7) cell line was purchased from ATCC. The *in vitro* anti-inflammatory activity of compounds **1–7** were measured by examining the inhibition of lipopolysaccharide (LPS) induced upregulation of iNOS (inducible nitric oxide synthetase)

and COX-2 (cyclo-oxygenase-2) proteins in macrophage cells using Western blotting analysis.<sup>39,40</sup>

### Acknowledgements

Financial support awarded to J.-H. Sheu were provided by the National Science Council (NSC-98-2113-M-110-002-MY3) and the Ministry of Education of Taiwan (98C031702).

### Notes and references

- J.-H. Sheu, C.-H. Chao, G.-H. Wang, K.-C. Hung, C.-Y. Duh, M. Y. Chiang, Y.-C. Wu and C.-C. Wu, *Tetrahedron Lett.*, 2004, **45**, 6413–6416.
- H.-C. Huang, Z.-H. Wen, C.-H. Chao, A. F. Ahmed, M. Y. Chiang, Y.-H. Kuo, C.-H. Hus and J.-H. Sheu, *Tetrahedron Lett.*, 2006, **47**, 8751–8755.
- Y. Lu, C.-Y. Huang, Y.-F. Lin, Z.-H. Wen, J.-H. Su, Y.-H. Kao, M.-Y. Chiang and J.-H. Sheu, *J. Nat. Prod.*, 2008, **71**, 1754–1759.
- C.-H. Chao, Z.-H. Wen, Y.-C. Wu, H.-C. Yeh and J.-H. Sheu, *J. Nat. Prod.*, 2008, **71**, 1819–1824.
- J.-H. Su, A. F. Ahmed, P.-J. Sung, C.-H. Chao, Y.-H. Kao and J.-H. Sheu, *J. Nat. Prod.*, 2006, **69**, 1134–1139.
- B.-W. Chen, C.-H. Chao, J.-H. Su, Z.-H. Wen, P.-J. Sung and J.-H. Sheu, *Org. Biomol. Chem.*, 2010, **8**, 2363–2366.
- B.-W. Chen, C.-H. Chao, J.-H. Su, C.-W. Tsai, W.-H. Wang, Z.-H. Wen, C.-Y. Huang, P.-J. Sung, Y.-C. Wu and J.-H. Sheu, *Org. Biomol. Chem.*, 2011, **9**, 834–844.
- B.-W. Chen, Y.-C. Wu, M. Y. Chiang, J.-H. Su, W.-H. Wang, T.-Y. Fan and J.-H. Sheu, *Tetrahedron*, 2009, **65**, 7016–7022.
- C.-H. Chao, Z.-H. Wen, I.-M. Chen, J.-H. Su, H.-C. Huang, M. Y. Chiang and J.-H. Sheu, *Tetrahedron*, 2008, **64**, 3554–3560.
- C.-H. Chao, Z.-H. Wen, J.-H. Su, I.-M. Chen, H.-C. Huang, C.-F. Dai and J.-H. Sheu, *Steroids*, 2008, **73**, 1353–1358.
- A. F. Ahmed, M.-H. Wu, Y.-C. Wu and J.-H. Sheu, *J. Chin. Chem. Soc.*, 2006, **53**, 489–494.
- H. M. Hassan, M. A. Khanfar, A. Y. Elnagar, R. Mohammed, L. A. Shaala, D. T. A. Youssef, M. S. Hifnawy and K. A. El Sayed, *J. Nat. Prod.*, 2010, **73**, 848–853.
- J. E. Hochlowski and D. J. Faulkner, *Tetrahedron Lett.*, 1980, **21**, 4055–4056.
- A. F. Ahmed, M.-H. Wu, G.-H. Wang, Y.-C. Wu and J.-H. Sheu, *J. Nat. Prod.*, 2005, **68**, 1051–1055.
- R. Kazlauskas, P. T. Murphy, R. J. Wells and P. Schönholzer, *Tetrahedron Lett.*, 1977, **18**, 4643–4646.
- N. S. Sarma, R. Chavakula and I. N. Rao, *J. Nat. Prod.*, 1993, **56**, 1977–1980.
- K. Yamada, N. Ogata, K. Ryu, T. Miyamoto, T. Komori and R. Higuchi, *J. Nat. Prod.*, 1997, **60**, 393–396.
- Y. Uchio, M. Kodama, S. Usui and Y. Fukazawa, *Tetrahedron Lett.*, 1992, **33**, 1317–1320.
- Y. Uchio, M. Nakatani, T. Hase, M. Kodama, S. Usui and Y. Fukazawa, *Tetrahedron Lett.*, 1989, **30**, 3331–3332.
- L. Chill, N. Berrer, Y. Benayahu and Y. Kashman, *J. Nat. Prod.*, 2005, **68**, 19–25.
- C. B. Rao, D. S. Rao, C. Satyanarayana, D. V. Rao, K. E. Kassühlke and D. J. Faulkner, *J. Nat. Prod.*, 1994, **57**, 574–580.
- D. S. Rao, C. Sreedhara, D. V. Rao and C. B. Rao, *Indian J. Chem. Sect. B*, 1994, **33B**, 198–199.
- G.-W. Zhang, X.-Q. Ma, H. Kurihara, C.-X. Zhang, X.-S. Yao, J.-Y. Su and L.-M. Zeng, *Org. Lett.*, 2005, **7**, 991–994.
- D. E. Williams, A. Amlani, A. S. Dewi, B. O. Patrick, L. van Ofwegen, A. L.-F. Mui and R. J. Andersen, *Aust. J. Chem.*, 2010, **63**, 895–900.
- Z.-H. Wen, C.-H. Chao, M.-H. Wu and J.-H. Sheu, *Eur. J. Med. Chem.*, 2010, **45**, 5998–6004.
- B.-W. Chen, S.-M. Chang, C.-Y. Huang, C.-H. Chao, J.-H. Su, Z.-H. Wen, C.-H. Hus, C.-F. Dai, Y.-C. Wu and J.-H. Sheu, *J. Nat. Prod.*, 2010, **73**, 1785–1791.
- M. Akin, V. Costantino, A. Mangoni, E. Fattorusso and E. M. Gaydou, *Steroids*, 1998, **63**, 575–578.
- M. Iwashima, K. Nara and K. Iguchi, *Steroids*, 2000, **65**, 130–137.

- 29 N. Koizumi, Y. Fujimoto, T. Takeshita and N. Ikekawa, *Chem. Pharm. Bull.*, 1979, **27**, 38–42.
- 30 I. Ohtani, T. Kusumi, Y. Kashman and H. Kakisawa, *J. Am. Chem. Soc.*, 1991, **113**, 4092–4096.
- 31 I. Ohtani, T. Kusumi, Y. Kashman and H. Kakisawa, *J. Org. Chem.*, 1991, **56**, 1296–1298.
- 32 C. Van Minh, N. X. Cuong, T. A. Tuan, E. M. Choi, Y. H. Kim and P. V. Kiem, *Nat. Prod. Commun.*, 2007, **2**, 1095–1100.
- 33 A. Migliuolo, V. Piccialli and D. Sica, *Steroids*, 1992, **57**, 344–347.
- 34 V. Anjaneyulu, K. Nageswara Rao, J. Suresh Babu and M. Kobayashi, *Indian J. Chem., Sect. B*, 1994, **33B**, 144–147.
- 35 A. S. R. Anjaneyulu, M. V. R. Krishna Murthy and G. V. Rao, *Tetrahedron*, 1997, **53**, 9301–9312.
- 36 P.-A. Blanc and C. Djerassi, *J. Am. Chem. Soc.*, 1980, **102**, 7113–7114.
- 37 M. C. Alley, D. A. Scudiero, A. Monks, M. L. Hursey, M. J. Czerwinski, D. L. Fine, B. J. Abbott, J. G. Mayo, R. H. Shoemaker and M. R. Boyd, *Cancer Res.*, 1988, **48**, 589–601.
- 38 D. A. Scudiero, R. H. Shoemaker, K. D. Paull, A. Monks, S. Tierney, T. H. Nofziger, M. J. Currens, D. Seniff and M. R. Boyd, *Cancer Res.*, 1988, **48**, 4827–4833.
- 39 Y.-H. Jean, W.-F. Chen, C.-S. Sung, C.-Y. Duh, S.-Y. Huang, C.-S. Lin, M.-H. Tai, S.-F. Tzeng and Z.-H. Wen, *Br. J. Pharmacol.*, 2009, **158**, 713–725.
- 40 Y.-H. Jean, W.-F. Chen, C.-Y. Duh, S.-Y. Huang, C.-H. Hsu, C.-S. Lin, C.-S. Sung, I.-M. Chen and Z.-H. Wen, *Eur. J. Pharmacol.*, 2008, **578**, 323–331.